Clinical Studies
Avanir Pharmaceuticals
Currently Enrolling!
- Indication: Alzheimer’s Disease with Agitation (MMSE 8-24, inclusive)
- Primary Objective of Study: Evaluate the efficacy, safety, and tolerability of A VP-786 compared to placebo for the treatment of agitation in patients with dementia of the Alzheimer’s type
- Study length: 20 weeks
- Study Design: 4-week screening, 12-week double-blind randomized in a 1:1 ratio receiving either: a) study drug, b) placebo. All groups orally ingest drug twice daily.
Individuals that meet requirements:
- Male or Female between 50-90, inclusive
- Must be diagnosed with probable Alzheimer’s Disease
- Must have clinically significant agitation at least 2 weeks prior to screening
Axsome Therapeutics, Inc
ADVANCE
Currently Enrolling!
Many individuals with Alzheimer’s Dementia may experience agitation in addition to memory and cognitive difficulties. If you or someone you know is struggling with symptoms of agitation, the ADVANCE study may be a good option for you. The purpose of this clinical trial is to evaluate the efficacy and safety of an investigational product for symptoms of agitation in those with Alzheimer’s.
Individuals that meet requirements:
- Are male or female, 65-90 years old
- Have a diagnosis of probable Alzheimer’s Dementia alongside symptoms of agitation
- Must have an available caregiver
- Currently take medication for Alzheimer’s (e.g., Donepezil, Memantine)
Axsome Therapeutics, Inc
Currently Enrolling!
- Indication: Alzheimer’s Disease with Agitation (MMSE 10-24, inclusive)
- Primary Objective of Study: To evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated with dementia of the Alzheimer’s type
- Study length: 9-26 weeks, with the option of 24 week open-label extension
- Study Design: 4-week screening, 9-week open-label period, then randomized in a 1: 1 ratio receiving either: a) study drug, b) placebo. All groups orally ingest drug twice daily.
Individuals that meet requirements:
- Male or Female between 65-90, inclusive
- Must be diagnosed with probable Alzheimer’s Disease
- Must have clinically significant agitation at time of screening
Otsuka CYPRESS PTSD Trial
Currently Enrolling!
If you’ve experienced or witnessed a traumatic event and now have unwanted memories of the event, struggle with fear and anxiety, feel isolated from family and friends; or avoid situations that remind you of the trauma, you may have post-traumatic stress disorder (PTSD).
Individuals that meet requirements:
- Are 18 to 65 years of age
- Have had PTSD symptoms for at least 6 months prior to this study
All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related travel may be provided.
Relmada Therapeutics
Currently Enrolling!
- Indication: Treatment Resistant Major Depressive Disorder
- Primary Objective of Study: To evaluate the therapeutic efficacy of REL-1017 as an adjunctive treatment versus placebo through Day 28 in the Montgomery-As berg Depression Rating Scale (MAD RS 10) total score
- Study Length: 11 weeks, with option of 1 year open-label study
- Study Design: 4-week screening, then randomized in a 1:1 ratio receiving either: a) 25mg study drug, b) placebo. All groups ingest drug orally once daily.
Individuals that meet requirements:
- Ambulatory female 18-45, inclusive
- Must be in current MDD episode 8 weeks-36 months in duration
- Must have BMI between 18 and 30kg/m2 at screening
- Must have inadequate response to 1-3 antidepressant therapies at screening
Sage Therapeutics, Inc
Currently Enrolling!
- Indication: Major Depressive Disorder
- Primary Objective of Study: To determine the safety and tolerability of initial treatment and re-treatment(s) with SAGE-217 in adults with Major Depressive Disorder (MDD)
- Study Length: 1 year (4 weeks of treatment and follow up, then 48 weeks of observation or retreatment)
- Study Design: 4-week screening, 14-day open-label treatment, then observed and re-treated as needed for 48 week observational period
Individuals that meet requirements:
- Male or female between 18 and 75, inclusive
- Must have diagnosis of MDD, but has not failed 2 more classes of medications in current episode
- Must be willing to abstain from drugs and alcohol for duration of study
- Must be on highly effective birth control regimen
Sage Therapeutics, Inc
Currently Enrolling!
- Indication: Postpartum Depression
- Primary Objective of Study: To determine if treatment with SAGE-217 reduces depressive symptoms in adults with severe postpartum depression compared to placebo
- Study Length: 11 weeks
- Study Design: 4-week screening, then randomized in a 1:1 ratio receiving either: a) 50mg study drug, b) placebo. All groups ingest drug orally for 14 days
Individuals that meet requirements:
- Ambulatory female 18-45, inclusive
- Must agree to stop breastfeeding infant prior to receiving drug through 7 days post-treatment
- Must be ≤ 12 months postpartum
- Must be on highly effective birth control regimen
Synaptogenix (Neurotrope Biosciences)
Currently Enrolling!
- Indication: Moderately Severe Alzheimer’s Disease (MMSE 10-18, inclusive)
- Primary Objective of Study: To evaluate the safety, tolerability, and long-term efficacy of bryostatin for the treatment of moderately severe Alzheimer’s disease
- Study length: 42 weeks
- Study Design: 4-week screening, then randomized in a 1:1 ratio receiving either: a) 20mcg study drug, b) placebo. All groups have two 13-week treatment periods, including 7 IV drug infusions each.
Individuals that meet requirements:
- Male or Female between 55-85, inclusive
- Must meet diagnostic criteria for probable Alzheimer’s Disease
- Must have MRI consistent with probable AD within 2 years of screening
UCB Biopharma
Currently Enrolling!
- Indication: Mild to Prodromal Alzheimer’s Disease (MMSE 20-30, inclusive)
- Primary Objective of Study: To investigate the effect of bepranemab (UCB0107) vs placebo on the CDR-SB up to Week 80 in participants with prodromal or mild AD
- Study length: 80 weeks, with the option of 72 week open-label study
- Study Design: 4-week screening, then randomized in a 1: 1: 1 ratio receiving either: a) low dose study drug, b) high dose study drug, c) placebo. All groups will receive 2-hour drug infusion every 4 weeks during the study.
Individuals that meet requirements:
- Male or Female between 50-80, inclusive
- Must meet diagnostic criteria for MCI due to AD or probable AD
- If on AD medication, must be on stable dose for at least 12 prior to screening
- Subject must be able to tolerate MRI and PET scans
No Longer Enrolling
Axsome Therapeutics, Inc
Individuals with Major Depressive Disorder (MDD) may have failed one or more anti-depressant in the past. Axsome is investigating the efficacy of a product in those who have treatment resistant MDD (STRIDE study). If you suffer from Major Depression and have not found success in one or more anti-depressant medications, you may qualify for AXSOME’S STRIDE study!
CHICKADEE Adolescent Females (under 18)
The Chickadee Study is a research study in teens with postpartum depression (PPD). You may qualify if you are 15 to 17 years old and have had a baby in the last six months.
Eisai DELPHIA Dementia with Lewy Bodies
The Delphia study will test an investigational medication to see if it might improve cognitive function, including attention, memory, and language in patients who have dementia with Lewy bodies (DLB).
Evaluating Gait and Balance in Subjects with Dementia
Several researchers have found that individuals diagnosed with dementia have a higher likelihood of experiencing episodes of falling or issues with balance. This study examined the effects of intepirdine (RVT-101) on gait and balance in individuals with Alzheimer’s Disease, Lewy Body Dementia, or Parkinson’s Dementia. More information about this study and its results can be found below by clicking on the following link(s).
Otsuka RELAPSE
If you have major depressive disorder (MDD) and are in a current depressive episode, we invite you to learn about a clinical trial of an investigational drug that is taken with your current antidepressant medication. In this trial, researchers will evaluate the safety and efficacy of the investigational drug as an add-on therapy to your current antidepressant medication. If you meet the requirements listed below, contact us to get more information.
GAIN Alzheimer's Trial
GAIN is a clinical trial evaluating whether an investigational oral drug is safe and can halt the progression of Alzheimer’s disease by reducing the damage caused by bacteria in the brain.
Hummingbird Postpartum Depression Trial
The Hummingbird study evaluated an investigational medication in women with moderate to severe postpartum depression. Postpartum depression is a biological complication of pregnancy, including symptoms of sadness, anger, loss of pleasure, and cognitive, emotional, physical symptoms. Over 100 women participated in the Hummingbird study across 22 states in the U.S. and over 40 different study sites. More information about the trial can be found below from the following link(s).
Mindset Study
MINDSET is phase II clinical research program that evaluated the investigational medication, RVT-101, for the treatment of mild-to-moderate Alzheimer’s Disease. Researchers investigated the efficacy of combining RVT-101 with Donepezil in cognitive abilities and performance on activities of daily living. This worldwide research trial enrolled over 1,000 participants across hundreds of research sites. More information on the MINDSET study can be found by clicking the link(s) below.
PrecisionMed Trial
This study involved administering several cognitive tests on individuals 50 years and older who have a diagnosis of Mild Alzheimer’s Disease or Mild Cognitive Impairment.
Reverse-SD
Those who have symptoms of cognitive declines, such as issues with thinking, judgment, or memory, may be experiencing Mild Cognitive Impairment (MCI) or have already been diagnosed with MCI. This clinical trial is evaluating an investigational drug for those who are experiencing MCI, or mild Alzheimer’s Dementia.
Sage Therapeutics Robin Study - Females 18 - 45
This research study is evaluating the efficacy and safety of an investigational oral medication in adult women from 18 to 45 with Postpartum Depression. An investigational medication is a study drug that will be tested during a study to see if it is safe and effective for a specific condition and/or group of people.
Shoreline Study
The Shoreline Study is evaluating an investigational oral medication to see if it reduces symptoms of moderate-to-severe depression.
Sprites Study
The SPRITES study examined how sertraline or psychotherapy affects aspects of cognitive, emotional, and physical development in children who are diagnosed with an anxiety, depressive, or obsessive-compulsive disorder. In addition, the study examined the long-term effects that sertraline may or may not have on children and adolescent development. If you would like to learn more about this study, please click the link(s) below.
Suvn Life Sciences Ltd.
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects from 50-85 years of age with moderate Alzheimer’s disease receiving stable doses of donepezil HCl and memantine HCl.
Teens and Young Adults Depression Study
This study examined the safety and efficacy for a non-drug therapy (i.e., NeuroStar TMS therapy) for teens or young adults suffering from depression. Study participants received the non-invasive, TMS treatment for no-cost. This non-drug treatment has been FDA-cleared for adults (22-70 years old). If you are interested in reading about the results of this study, or wish to know more information about NeuroStar TMS therapy for the treatment of depression, please click the link(s) below.
Find Out More
Please call or email Anchor Neuroscience research staff if you are interested in learning more about studies for which you may quality or to be placed on our list of potential study subjects.
- 850.433.6760
- info@anchorneuroscience.com
- Find us on Facebook